Epilepsy in adults

Roland D. Thijs, Rainer Surges, Terence J. O'Brien, Josemir W. Sander

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Epilepsy is one of the most common serious brain conditions, affecting over 70 million people worldwide. Its incidence has a bimodal distribution with the highest risk in infants and older age groups. Progress in genomic technology is exposing the complex genetic architecture of the common types of epilepsy, and is driving a paradigm shift. Epilepsy is a symptom complex with multiple risk factors and a strong genetic predisposition rather than a condition with a single expression and cause. These advances have resulted in the new classification of epileptic seizures and epilepsies. A detailed clinical history and a reliable eyewitness account of a seizure are the cornerstones of the diagnosis. Ancillary investigations can help to determine cause and prognosis. Advances in brain imaging are helping to identify the structural and functional causes and consequences of the epilepsies. Comorbidities are increasingly recognised as important aetiological and prognostic markers. Antiseizure medication might suppress seizures in up to two-thirds of all individuals but do not alter long-term prognosis. Epilepsy surgery is the most effective way to achieve long-term seizure freedom in selected individuals with drug-resistant focal epilepsy, but it is probably not used enough. With improved understanding of the gradual development of epilepsy, epigenetic determinants, and pharmacogenomics comes the hope for better, disease-modifying, or even curative, pharmacological and non-pharmacological treatment strategies. Other developments are clinical implementation of seizure detection devices and new neuromodulation techniques, including responsive neural stimulation.

Original languageEnglish
Pages (from-to)689-701
Number of pages13
JournalThe Lancet
Volume393
Issue number10172
DOIs
Publication statusPublished - 16 Feb 2019

Cite this

Thijs, R. D., Surges, R., O'Brien, T. J., & Sander, J. W. (2019). Epilepsy in adults. The Lancet, 393(10172), 689-701. https://doi.org/10.1016/S0140-6736(18)32596-0
Thijs, Roland D. ; Surges, Rainer ; O'Brien, Terence J. ; Sander, Josemir W. / Epilepsy in adults. In: The Lancet. 2019 ; Vol. 393, No. 10172. pp. 689-701.
@article{8cb8fe2e9ecc4a0aab272a1ca5eb51fc,
title = "Epilepsy in adults",
abstract = "Epilepsy is one of the most common serious brain conditions, affecting over 70 million people worldwide. Its incidence has a bimodal distribution with the highest risk in infants and older age groups. Progress in genomic technology is exposing the complex genetic architecture of the common types of epilepsy, and is driving a paradigm shift. Epilepsy is a symptom complex with multiple risk factors and a strong genetic predisposition rather than a condition with a single expression and cause. These advances have resulted in the new classification of epileptic seizures and epilepsies. A detailed clinical history and a reliable eyewitness account of a seizure are the cornerstones of the diagnosis. Ancillary investigations can help to determine cause and prognosis. Advances in brain imaging are helping to identify the structural and functional causes and consequences of the epilepsies. Comorbidities are increasingly recognised as important aetiological and prognostic markers. Antiseizure medication might suppress seizures in up to two-thirds of all individuals but do not alter long-term prognosis. Epilepsy surgery is the most effective way to achieve long-term seizure freedom in selected individuals with drug-resistant focal epilepsy, but it is probably not used enough. With improved understanding of the gradual development of epilepsy, epigenetic determinants, and pharmacogenomics comes the hope for better, disease-modifying, or even curative, pharmacological and non-pharmacological treatment strategies. Other developments are clinical implementation of seizure detection devices and new neuromodulation techniques, including responsive neural stimulation.",
author = "Thijs, {Roland D.} and Rainer Surges and O'Brien, {Terence J.} and Sander, {Josemir W.}",
year = "2019",
month = "2",
day = "16",
doi = "10.1016/S0140-6736(18)32596-0",
language = "English",
volume = "393",
pages = "689--701",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "10172",

}

Thijs, RD, Surges, R, O'Brien, TJ & Sander, JW 2019, 'Epilepsy in adults', The Lancet, vol. 393, no. 10172, pp. 689-701. https://doi.org/10.1016/S0140-6736(18)32596-0

Epilepsy in adults. / Thijs, Roland D.; Surges, Rainer; O'Brien, Terence J.; Sander, Josemir W.

In: The Lancet, Vol. 393, No. 10172, 16.02.2019, p. 689-701.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Epilepsy in adults

AU - Thijs, Roland D.

AU - Surges, Rainer

AU - O'Brien, Terence J.

AU - Sander, Josemir W.

PY - 2019/2/16

Y1 - 2019/2/16

N2 - Epilepsy is one of the most common serious brain conditions, affecting over 70 million people worldwide. Its incidence has a bimodal distribution with the highest risk in infants and older age groups. Progress in genomic technology is exposing the complex genetic architecture of the common types of epilepsy, and is driving a paradigm shift. Epilepsy is a symptom complex with multiple risk factors and a strong genetic predisposition rather than a condition with a single expression and cause. These advances have resulted in the new classification of epileptic seizures and epilepsies. A detailed clinical history and a reliable eyewitness account of a seizure are the cornerstones of the diagnosis. Ancillary investigations can help to determine cause and prognosis. Advances in brain imaging are helping to identify the structural and functional causes and consequences of the epilepsies. Comorbidities are increasingly recognised as important aetiological and prognostic markers. Antiseizure medication might suppress seizures in up to two-thirds of all individuals but do not alter long-term prognosis. Epilepsy surgery is the most effective way to achieve long-term seizure freedom in selected individuals with drug-resistant focal epilepsy, but it is probably not used enough. With improved understanding of the gradual development of epilepsy, epigenetic determinants, and pharmacogenomics comes the hope for better, disease-modifying, or even curative, pharmacological and non-pharmacological treatment strategies. Other developments are clinical implementation of seizure detection devices and new neuromodulation techniques, including responsive neural stimulation.

AB - Epilepsy is one of the most common serious brain conditions, affecting over 70 million people worldwide. Its incidence has a bimodal distribution with the highest risk in infants and older age groups. Progress in genomic technology is exposing the complex genetic architecture of the common types of epilepsy, and is driving a paradigm shift. Epilepsy is a symptom complex with multiple risk factors and a strong genetic predisposition rather than a condition with a single expression and cause. These advances have resulted in the new classification of epileptic seizures and epilepsies. A detailed clinical history and a reliable eyewitness account of a seizure are the cornerstones of the diagnosis. Ancillary investigations can help to determine cause and prognosis. Advances in brain imaging are helping to identify the structural and functional causes and consequences of the epilepsies. Comorbidities are increasingly recognised as important aetiological and prognostic markers. Antiseizure medication might suppress seizures in up to two-thirds of all individuals but do not alter long-term prognosis. Epilepsy surgery is the most effective way to achieve long-term seizure freedom in selected individuals with drug-resistant focal epilepsy, but it is probably not used enough. With improved understanding of the gradual development of epilepsy, epigenetic determinants, and pharmacogenomics comes the hope for better, disease-modifying, or even curative, pharmacological and non-pharmacological treatment strategies. Other developments are clinical implementation of seizure detection devices and new neuromodulation techniques, including responsive neural stimulation.

UR - http://www.scopus.com/inward/record.url?scp=85061398477&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(18)32596-0

DO - 10.1016/S0140-6736(18)32596-0

M3 - Review Article

VL - 393

SP - 689

EP - 701

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10172

ER -

Thijs RD, Surges R, O'Brien TJ, Sander JW. Epilepsy in adults. The Lancet. 2019 Feb 16;393(10172):689-701. https://doi.org/10.1016/S0140-6736(18)32596-0